# Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

> **NCT05672927** · PHASE4 · RECRUITING · sponsor: **The University of Texas Medical Branch, Galveston** · enrollment: 618 (estimated)

## Conditions studied

- Immunization
- HPV Infection
- Human Papillomavirus

## Interventions

- **BIOLOGICAL:** 9-valent HPV vaccine, 2 doses alternate timing
- **BIOLOGICAL:** 9-valent HPV vaccine, 3 doses standard timing

## Key facts

- **NCT ID:** NCT05672927
- **Lead sponsor:** The University of Texas Medical Branch, Galveston
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-18
- **Primary completion:** 2026-08
- **Final completion:** 2027-08
- **Target enrollment:** 618 (ESTIMATED)
- **Last updated:** 2025-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05672927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05672927, "Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05672927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*